Volume 1.21 | Oct 26

Dermal Cell News 1.21 October 26, 2015
Dermal Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  DCN on Twitter
Blocking Enzymes in Hair Follicles Promotes Hair Growth
Researchers found that inhibiting a family of enzymes inside hair follicles that are suspended in a resting state restores hair growth. In experiments with mouse and human hair follicles, they found that drugs that inhibit the Janus kinase family of enzymes promote rapid and robust hair growth when applied to the skin. [Press release from Columbia University discussing online prepublication in Science Advances]
Press Release | Full Article | Video
Learn More: Standardized Tools for Cancer Research
PUBLICATIONS (Ranked by impact factor of the journal)

IL-33-Dependent Group 2 Innate Lymphoid Cells Promote Cutaneous Wound Healing
Investigators demonstrated that cutaneous injury promotes an IL-33-dependent group 2 innate lymphoid cell response and that abrogation of this response impairs re-epithelialization and efficient wound closure. [J Invest Dermatol] Abstract

Dynamics of Lgr6+ Progenitor Cells in the Hair Follicle, Sebaceous Gland, and Interfollicular Epidermis
Researchers used multicolor lineage tracing to mark Lgr6-expressing basal cells in the hair follicle isthmus, sebaceous gland, and interfollicular epidermis. [Stem Cell Reports] Full Article | Graphical Abstract

Pro-Apoptotic Effect of Control-Released Basic Fibroblast Growth Factor on Skin Wound Healing in a Diabetic Mouse Model
Researchers aimed to enhance skin wound healing in a diabetes mouse model while concomitantly decreasing scar formation by using control-released basic fibroblast growth factor together with acidic gelatin hydrogel microspheres. [Wound Repair Regen] Abstract

Epigallocatechin-3-Gallate Attenuates the AIM2-Induced Secretion of IL-1β in Human Epidermal Keratinocytes
Scientists investigated the issue of whether or how epigallocatechin-3-gallate suppresses absent in melanoma 2 (AIM2) inflammasome in human epidermal keratinocytes. [Biochem Biophys Res Commun] Abstract


Overshoot during Phenotypic Switching of Cancer Cell Populations
Researchers sorted human melanoma cells using three distinct cancer stem cell (CSC) markers—CXCR6, CD271 and ABCG2—and observed that the fraction of non-CSC-marked cells first overshoots to a higher level and then returns to the level of unsorted cells. [Sci Rep] Full Article

Abnormal Regulation of Fibronectin Production by Fibroblasts in Psoriasis
Researchers investigated the expression of KGF, FGFR2, fibronectin (FN) and EDA+ FN in healthy and non-lesional psoriatic skin and studied the effect of KGF on the regulation of FN and EDA+ FN production by fibroblasts. [Br J Dermatol] Full Article

Withaferin A Suppresses the Up-Regulation of Acetyl-CoA Carboxylase 1 and Skin Tumor Formation in a Skin Carcinogenesis Mouse Model
Withaferin A’s (WA) chemopreventive potential was tested in a chemically-induced skin carcinogenesis mouse model. Pathological examinations revealed that WA significantly suppressed skin tumor formation. [Mol Carcinog] Abstract

Diagnostic and Prognostic Potentials of KLF6 and HER3 Expression Alterations in Cutaneous Malignant Melanoma
The authors evaluated the presence of Kruppel-like factor 6 (KLF6) and human epidermal growth factor receptor 3 (HER3) in patients with cutaneous malignant melanoma and clinical significance of these markers. [Tumor Biol] Abstract

Weekend-Free Culture hPSCs with mTeSR™1 or TeSR™-E8™
The Two Faces of the Inflammasome Adaptor ASC in Epithelial Skin Carcinogenesis
Scientists discuss current knowledge on the role of inflammasomes in epithelial cancer of the gut and skin with a special focus on the complex role of the inflammasome adaptor ASC in epithelial skin carcinogenesis. [Clin Exp Rheumatol] Abstract

Visit our reviews page to see a complete list of reviews in the dermal cell research field.
A Subset of Patients with Metastatic Melanoma Achieves Clinical Benefit from Combination of Immunotherapy and Radiation Therapy
Immunotherapy combined with palliative radiation therapy for a subset of patients with metastatic melanoma reduces the growth and spread of the cancer. [Press release from the American Society for Radiation Oncology (ASTRO) discussing research presented at the 57th ASTRO Annual Meeting, San Antonio] Press Release

From our sponsor: Learn about assays for cord blood. Download the free Technical Bulletin.
Rock Creek Pharmaceuticals Announces Successful Completion of Phase I Clinical Trial to Evaluate Oral Formulations of Its Lead Compound, Plans to Conduct Proof-of-Concept Trial in Subjects with Mild to Moderate Psoriasis
Rock Creek Pharmaceuticals, Inc. announced the successful completion of its three part Phase I clinical trial. The overall objective of the Phase I trial was to evaluate safety, tolerability and pharmacokinetic profiles of different formulations of the company’s lead compound, anatabine citrate, in healthy volunteers. [Rock Creek Pharmaceuticals, Inc.] Press Release

First Participants Enrolled in RepliCel’s Phase I Clinical Trial of its RCS-01 Dermatology Injectable
RepliCel Life Sciences Inc. announced that the first three participants in the Phase I clinical trial evaluating its RCS-01 product have been enrolled, and their tissue biopsies sent for processing prior to intra-dermal injections. [RepliCel Life Sciences Inc.] Press Release

RXi Pharmaceuticals Announces Positive Interim Results in Phase IIa Dermatology Program with RXI-109
RXi Pharmaceuticals Corporation announced that results from a blinded panel and an investigator review show that incision sites treated with RXI-109 after scar revision surgery achieved better scores as compared to control incision sites in the same subjects, three months post scar revision surgery. [RXi Pharmaceuticals Corporation] Press Release

Amgen Receives CHMP Positive Opinion For IMLYGIC™ (Talimogene Laherparepvec)
Amgen announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency, has adopted a positive opinion recommending that IMLYGIC™ be granted approval for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic with no bone, brain, lung or other visceral disease. [Amgen Inc.] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Keystone Symposium – Cancer Immunotherapy: Immunity and Immunosuppression Meet Targeted Therapies
January 24-28, 2016
Vancouver, Canada

Visit our events page to see a complete list of events in the dermal cell community.
NEW Postdoctoral Position – Genetic Skin Diseases (Inserm)

Faculty Position – Stem Cell and Regenerative Medicine (King Abdullah University of Science and Technology)

Postdoctoral Associate – Dermatology (University of Pittsburgh)

Research Technician II – Stem Cell and Gene Therapy (Fred Hutchinson Cancer Research Center)

Postdoctoral Position – Tissue Engineering and Regenerative Medicine (Northwestern University)

Postdoctoral Position – Medicinal Chemistry (Auburn University)

Independent Junior Group Leader – Human Genetics of Inflammatory Skin Diseases (University of Lübeck)

Postdoctoral Position – Cancer and Developmental Biology (University of California, Irvine)

Assistant Professor – Stem Cell Biology (University of South Carolina)

Postdoctoral Fellow – Cancer Genetics (Feinberg School of Medicine)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Dermal Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Dermal Cell News: Archives | Events | Contact Us